As companies around the world scramble to develop a vaccine against the new strain of coronavirus, now known as SARS-CoV-2, Codagenix Inc. Inc., a US-based clinical-stage biotechnology company, along with partner Serum Institute of India Ltd., is throwing its hat in the ring.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?